Overview

Trial of NovoSeven® in Haemophilia - Joint Bleeds

Status:
Completed
Trial end date:
2006-02-01
Target enrollment:
0
Participant gender:
Male
Summary
This trial is conducted in the United States of America (USA). This study compares the effectiveness and safety of NovoSeven® to FEIBA (FEIBA VH) in haemophilia patients with inhibitors being treated for joint bleeds.
Phase:
Phase 4
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Novo Nordisk A/S
Treatments:
Anti-inhibitor coagulant complex
Criteria
Inclusion Criteria:

- Diagnosis of hemophilia A or B with inhibitors to factor VIII or IX, respectively